Catégorie : News_Corporate
-
Advanced BioDesign joins forces with GTP Bioways to startmanufacturing of its innovative treatment for Acute MyeloidLeukemia (AML)
Lyon, Toulouse (France), March 27, 2024 – Advanced BioDesign, a biotech company specializing in the development of new therapeutic approaches to resistant cancers, and GTP Bioways, a CDMO (ContractDevelopment Manufacturing Organisation) specializing in the anufacture of innovative therapies, today announced their collaboration to meet the crucial needs of the first-in-human ODYSSEY study, aimed at treating…
-
Advanced BioDesign, winner of the France 2030 plan’s call for « i-DEMO » projects to finance its « Odyssey » clinical trial with up to €3M
Advanced BioDesign’s winning project is its first-in-human clinical trial of its drug candidate ABD-3001 for patients with acute myeloid leukaemia (AML) who are resistant to standard treatments.As part of the France 2030 plan, the « i-Demo » scheme supports the development of highly innovative, high added-value products and services to strengthen France’s scientific and technological capabilities. Lyon,…
Advanced BioDesign 